Acurx Pharmaceuticals Faces AI-Driven Challenges Amid Regulatory and Cybersecurity Concerns

Acurx Pharmaceuticals Llc (ACXP) has disclosed a new risk, in the Cyber Security category.

Acurx Pharmaceuticals Llc faces significant risks and challenges associated with the development and use of artificial intelligence, which could impact its business operations. The uncertain regulatory environment, exemplified by the EU AI Act, may impose additional compliance burdens and costs. Furthermore, the incorporation of generative AI tools by vendors and suppliers without adequate disclosure or adherence to privacy standards could lead to reputational harm and potential liability. The threat of cybersecurity incidents involving AI could result in the loss of intellectual property and confidential information, further damaging the company’s reputation and operational effectiveness.

The average ACXP stock price target is $4.83, implying 992.76% upside potential.

To learn more about Acurx Pharmaceuticals Llc’s risk factors, click here.